Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
HCWB | US
0.02
3.08%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.54
0.52
0.54
0.52
HCW Biologics Inc. a clinical-stage biopharmaceutical company focuses on discovering and developing novel immunotherapies for chronic low-grade inflammation and age-related diseases. The company's lead products include HCW9218 which is an injectable immunotherapeutic for patients with pancreatic ovarian breast prostate and colorectal cancers as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases such as alopecia areata and metabolic diseases. It also develops HCW9201 a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar Florida.
View LessLow Debt to Equity (< 0.25)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
142.0%1 month
121.0%3 months
137.9%6 months
116.6%-
-
2.80
-1.59
0.37
-3.63
7.66
-
-36.58M
23.39M
23.39M
-
-2.24K
-
-0.60
-344.32
0.87
0.14
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.21
Range1M
0.27
Range3M
0.30
Rel. volume
0.08
Price X volume
932.81
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| CytoMed Therapeutics Limited Ordinary Shares | GDTC | Biotechnology | 2.22 | 25.62M | 0.00% | n/a | 3.98% |
| Iterum Therapeutics plc | ITRM | Biotechnology | 1.12 | 25.43M | -4.27% | n/a | -198.11% |
| Caladrius Biosciences Inc | LSTA | Biotechnology | 2.98 | 24.79M | 0.34% | n/a | 0.58% |
| Common Stock | NRBO | Biotechnology | 2.92 | 24.78M | -3.63% | n/a | 0.90% |
| Bolt Technology Corp | BOLT | Biotechnology | 0.6376 | 24.40M | 1.79% | n/a | 22.00% |
| RenovoRx Inc. Common Stock | RNXT | Biotechnology | 0.9949 | 23.86M | -0.51% | n/a | 0.00% |
| Unity Biotechnology Inc | UBX | Biotechnology | 1.4 | 23.59M | 0.00% | n/a | 109.64% |
| Aligos Therapeutics Inc | ALGS | Biotechnology | 7.29 | 23.30M | 0.55% | n/a | 14.63% |
| Cyclo Therapeutics Inc | CYTH | Biotechnology | 0.81 | 23.24M | 4.65% | n/a | -58.50% |
| Spruce Biosciences Inc | SPRB | Biotechnology | 0.5467 | 22.58M | 5.34% | n/a | 6.24% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 13.44 | 20.47M | 4.19% | n/a | 204.46% |
| ILAG | ILAG | Building Products & Equipment | 1 | 18.06M | -2.91% | n/a | 5.48% |
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -3.63 | - | Cheaper |
| Ent. to Revenue | 7.66 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.80 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 137.93 | - | Riskier |
| Debt to Equity | -1.59 | -1.23 | Cheaper |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 23.39M | - | Emerging |